Cellectis CLLS Institutional Ownership

Cellectis S.A. (NASDAQ:CLLS) has 27 institutional investors with active 13F positions as of June 2026.

• These investors collectively held 9.5% of Cellectis's outstanding shares in June 2026, down from 10.2% in March 2026.
• They decreased total shares held in CLLS by -6.64% quarter over quarter, and investors in Cellectis increased 12.5% from a year ago.
• Among the 27 funds, 5 bought more Cellectis shares, 10 sold down, and 12 held their ground.
• Altogether, these fund groups held 9.48Mn shares in CLLS by June 2026, down by 673.98K shares quarter on quarter, and down 2.18Mn shares year over year.
• B Group, Inc. is the top holder of Cellectis as of June 30, 2026, with 3.28Mn shares representing 3.27% of outstanding stock.
• Top purchasers of CLLS stock for the quarter ending June 2026 included UBS Group AG (4.15K), Royal Bank Of Canada (1.56K), LPL Financial LLC (70), JONES FINANCIAL COMPANIES LLLP (50), Caitong International Asset Management Co., Ltd (49).
• Top sellers of CLLS stock for the quarter ending June 2026 included UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (533.74K), BlackRock, Inc. (116.08K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (15.49K), EverSource Wealth Advisors, LLC (5.07K), XTX Topco Ltd (3.99K).
• Cellectis's 10 largest shareholders as of June 2026 include B Group, Inc. (3.28Mn), Long Focus Capital Management, LLC (2.74Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.64Mn), NOMURA ASSET MANAGEMENT INTERNATIONAL INC. (226.88K), BlackRock, Inc. (225.44K), Morgan Stanley (85.46K), LPL Financial LLC (84.42K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (50.45K), BNP PARIBAS FINANCIAL MARKETS (40.1K), UBS Group AG (33.93K) per Business Quant data.